Stockreport
Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters]
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Biogen beats profit estimates on demand for multiple sclerosis drug (Reuters) - Biogen Inc beat Wall Street expectations for quarterly profit on Thursday, driven by demand for its top-selling multiple sclerosis drug, Tecfidera. Tecfidera revenue rose 4.5% to $1.16 billion, ahead of Street estimates of $1.12 billion and at a time when the drug faces patent challenges and increasing competition from newer treatments, including Roche Holding AG’s Ocrevus. Sales of Spinraza, the first approved treatment for spinal muscular atrophy, rose to $543.2 million, but missed the average analysts’ estimate of $549 million, according to Refinitiv data. The company said it expects 2020 full-year adjusted profit to be in the range of $31.50 per share and $33.50 per share. Analysts on average were expecting $33.03 per share. Net income attributable to the company rose to $1.44 billion, or $8.08 per share, in the quarter ended Dec. 31, from $946.8 million, or $4.73 per share, a year earlier when it paid
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BIIB | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BIIB alerts
BIIB alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
NEWS
NEWS
- Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting[GlobeNewswire]
- Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025[PR Newswire]
- New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aß Protofibrils in CSF[PR Newswire]
- Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting [Yahoo! Finance][Yahoo! Finance]
- Biogen (NASDAQ:BIIB) had its price target raised by analysts at Jefferies Financial Group Inc. from $190.00 to $210.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
BIIB
SEC Filings
SEC Filings
- 12/3/25 - Form 4
- 11/13/25 - Form SCHEDULE
- 11/10/25 - Form SCHEDULE
- BIIB's page on the SEC website
- More